Cargando…
Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells
DNA Topoisomerase IIα (TOP2α/170) is an enzyme essential for proliferating cells. For rapidly multiplying malignancies, this has made TOP2α/170 an important target for etoposide and other clinically active anticancer drugs. Efficacy of these agents is often limited by chemoresistance related to alte...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135202/ https://www.ncbi.nlm.nih.gov/pubmed/35617303 http://dx.doi.org/10.1371/journal.pone.0265794 |
_version_ | 1784713909424357376 |
---|---|
author | Hernandez, Victor A. Carvajal-Moreno, Jessika Wang, Xinyi Pietrzak, Maciej Yalowich, Jack C. Elton, Terry S. |
author_facet | Hernandez, Victor A. Carvajal-Moreno, Jessika Wang, Xinyi Pietrzak, Maciej Yalowich, Jack C. Elton, Terry S. |
author_sort | Hernandez, Victor A. |
collection | PubMed |
description | DNA Topoisomerase IIα (TOP2α/170) is an enzyme essential for proliferating cells. For rapidly multiplying malignancies, this has made TOP2α/170 an important target for etoposide and other clinically active anticancer drugs. Efficacy of these agents is often limited by chemoresistance related to alterations in TOP2α/170 expression levels. Our laboratory recently demonstrated reduced levels of TOP2α/170 and overexpression of a C-terminal truncated 90-kDa isoform, TOP2α/90, due to intronic polyadenylation (IPA; within intron 19) in an acquired etoposide-resistant K562 clonal cell line, K/VP.5. We previously reported that this isoform heterodimerized with TOP2α/170 and was a determinant of acquired resistance to etoposide. Optimization of the weak TOP2α exon 19/intron 19 5′ splice site in drug-resistant K/VP.5 cells by gene-editing restored TOP2α/170 levels, diminished TOP2α/90 expression, and circumvented drug resistance. Conversely, in the present study, silencing of the exon 19/intron 19 5′ splice site in parental K562 cells by CRISPR/Cas9 with homology-directed repair (HDR), and thereby forcing intron 19 retention, was used to induce resistance by disrupting normal RNA processing (i.e., gene knockout), and to further evaluate the role of TOP2α/170 and TOP2α/90 isoforms as resistance determinants. Gene-edited clones were identified by quantitative polymerase chain reaction (qPCR) and verified by Sanger sequencing. TOP2α/170 mRNA/protein expression levels were attenuated in the TOP2α gene-edited clones which resulted in resistance to etoposide as assessed by reduced etoposide-induced DNA damage (γH2AX, Comet assays) and growth inhibition. RNA-seq and qPCR studies suggested that intron 19 retention leads to decreased TOP2α/170 expression by degradation of the TOP2α edited mRNA transcripts. Forced expression of TOP2α/90 in the gene-edited K562 cells further decreased etoposide-induced DNA damage in support of a dominant negative role for this truncated isoform. Together results support the important role of both TOP2α/170 and TOP2α/90 as determinants of sensitivity/resistance to TOP2α-targeting agents. |
format | Online Article Text |
id | pubmed-9135202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-91352022022-05-27 Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells Hernandez, Victor A. Carvajal-Moreno, Jessika Wang, Xinyi Pietrzak, Maciej Yalowich, Jack C. Elton, Terry S. PLoS One Research Article DNA Topoisomerase IIα (TOP2α/170) is an enzyme essential for proliferating cells. For rapidly multiplying malignancies, this has made TOP2α/170 an important target for etoposide and other clinically active anticancer drugs. Efficacy of these agents is often limited by chemoresistance related to alterations in TOP2α/170 expression levels. Our laboratory recently demonstrated reduced levels of TOP2α/170 and overexpression of a C-terminal truncated 90-kDa isoform, TOP2α/90, due to intronic polyadenylation (IPA; within intron 19) in an acquired etoposide-resistant K562 clonal cell line, K/VP.5. We previously reported that this isoform heterodimerized with TOP2α/170 and was a determinant of acquired resistance to etoposide. Optimization of the weak TOP2α exon 19/intron 19 5′ splice site in drug-resistant K/VP.5 cells by gene-editing restored TOP2α/170 levels, diminished TOP2α/90 expression, and circumvented drug resistance. Conversely, in the present study, silencing of the exon 19/intron 19 5′ splice site in parental K562 cells by CRISPR/Cas9 with homology-directed repair (HDR), and thereby forcing intron 19 retention, was used to induce resistance by disrupting normal RNA processing (i.e., gene knockout), and to further evaluate the role of TOP2α/170 and TOP2α/90 isoforms as resistance determinants. Gene-edited clones were identified by quantitative polymerase chain reaction (qPCR) and verified by Sanger sequencing. TOP2α/170 mRNA/protein expression levels were attenuated in the TOP2α gene-edited clones which resulted in resistance to etoposide as assessed by reduced etoposide-induced DNA damage (γH2AX, Comet assays) and growth inhibition. RNA-seq and qPCR studies suggested that intron 19 retention leads to decreased TOP2α/170 expression by degradation of the TOP2α edited mRNA transcripts. Forced expression of TOP2α/90 in the gene-edited K562 cells further decreased etoposide-induced DNA damage in support of a dominant negative role for this truncated isoform. Together results support the important role of both TOP2α/170 and TOP2α/90 as determinants of sensitivity/resistance to TOP2α-targeting agents. Public Library of Science 2022-05-26 /pmc/articles/PMC9135202/ /pubmed/35617303 http://dx.doi.org/10.1371/journal.pone.0265794 Text en © 2022 Hernandez et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hernandez, Victor A. Carvajal-Moreno, Jessika Wang, Xinyi Pietrzak, Maciej Yalowich, Jack C. Elton, Terry S. Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells |
title | Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells |
title_full | Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells |
title_fullStr | Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells |
title_full_unstemmed | Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells |
title_short | Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells |
title_sort | use of crispr/cas9 with homology-directed repair to silence the human topoisomerase iiα intron-19 5’ splice site: generation of etoposide resistance in human leukemia k562 cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135202/ https://www.ncbi.nlm.nih.gov/pubmed/35617303 http://dx.doi.org/10.1371/journal.pone.0265794 |
work_keys_str_mv | AT hernandezvictora useofcrisprcas9withhomologydirectedrepairtosilencethehumantopoisomeraseiiaintron195splicesitegenerationofetoposideresistanceinhumanleukemiak562cells AT carvajalmorenojessika useofcrisprcas9withhomologydirectedrepairtosilencethehumantopoisomeraseiiaintron195splicesitegenerationofetoposideresistanceinhumanleukemiak562cells AT wangxinyi useofcrisprcas9withhomologydirectedrepairtosilencethehumantopoisomeraseiiaintron195splicesitegenerationofetoposideresistanceinhumanleukemiak562cells AT pietrzakmaciej useofcrisprcas9withhomologydirectedrepairtosilencethehumantopoisomeraseiiaintron195splicesitegenerationofetoposideresistanceinhumanleukemiak562cells AT yalowichjackc useofcrisprcas9withhomologydirectedrepairtosilencethehumantopoisomeraseiiaintron195splicesitegenerationofetoposideresistanceinhumanleukemiak562cells AT eltonterrys useofcrisprcas9withhomologydirectedrepairtosilencethehumantopoisomeraseiiaintron195splicesitegenerationofetoposideresistanceinhumanleukemiak562cells |